EFFECT OF ICRF-159 ON ACCUMULATION AND REPAIR OF RADIATION-DAMAGE

被引:0
作者
TAYLOR, IW [1 ]
BLEEHEN, NM [1 ]
机构
[1] UNIV CAMBRIDGE,SCH MED,MRC,CLIN ONCOL & RADIOTHERAPEUT UNIT,CAMBRIDGE,ENGLAND
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:421 / 421
页数:1
相关论文
共 50 条
[31]   INFLUENCE OF ICRF-159 OR ICRF-186 ON CYTO-TOXICITY OF DAUNORUBICIN AND DOXORUBICIN [J].
SUPINO, R .
TUMORI, 1984, 70 (02) :121-126
[32]   ICRF-159 IN ADVANCED GASTRIC-CANCER - ABSENCE OF ACTIVITY [J].
KRASNOW, S ;
BUNN, PA ;
IHDE, DC ;
MATTHEWS, MJ ;
COHEN, MH ;
EDDY, J ;
MINNA, JD .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1982, 5 (06) :635-639
[33]   STUDIES IN MICE TREATED WITH ICRF-159 COMBINED WITH DAUNORUBICIN OR DOXORUBICIN [J].
GIULIANI, F ;
CASAZZA, AM ;
DIMARCO, A ;
SAVI, G .
CANCER TREATMENT REPORTS, 1981, 65 (3-4) :267-276
[34]   LIMITED ACTIVITY OF ICRF-159 IN ADVANCED ACUTE-LEUKEMIA [J].
BAKOWSKI, MT ;
PRENTICE, HG ;
LISTER, TA ;
MALPAS, JS ;
MCELWAIN, TJ ;
POWLES, RL .
CANCER TREATMENT REPORTS, 1979, 63 (01) :127-129
[35]   BIS-DIKETOPIPERAZINE DERIVATIVES IN CLINICAL ONCOLOGY - ICRF-159 [J].
POSTER, DS ;
PENTA, J ;
MARSONI, S ;
BRUNO, S ;
MACDONALD, JS .
CANCER CLINICAL TRIALS, 1980, 3 (04) :315-320
[36]   INHIBITION OF CARDIOTOXIC, NEPHROTOXIC AND NEUROTOXIC EFFECTS OF DOXORUBICIN BY ICRF-159 [J].
HU, ST ;
BRANDLE, E ;
ZBINDEN, G .
PHARMACOLOGY, 1983, 26 (04) :210-220
[37]   RADIOTHERAPY AND ICRF-159 IN TREATMENT OF SOFT-TISSUE SARCOMAS [J].
RYALL, RDH .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1978, 4 (1-2) :133-134
[38]   TREATMENT OF KAPOSIS SARCOMA WITH ICRF-159 (NSC-129943) [J].
OLWENY, CLM ;
MASABA, JP ;
SIKYEWUNDA, W ;
TOYA, T .
CANCER TREATMENT REPORTS, 1976, 60 (01) :111-113
[39]   RAZOXANE (ICRF-159) DELAYS APPEARANCE OF COLORECTAL LIVER METASTASES [J].
TAYLOR, RH ;
GILBERT, JM ;
EVANS, MGC ;
LANE, HG .
GUT, 1985, 26 (05) :A572-A572
[40]   BIOLOGICAL PROPERTIES OF ICRF-159 AND RELATED BIS(DIOXOPIPERAZINE) COMPOUNDS [J].
HERMAN, EH ;
WITIAK, DT ;
HELLMANN, K ;
WARAVDEKAR, VS .
ADVANCES IN PHARMACOLOGY AND CHEMOTHERAPY, 1982, 19 :249-290